The effects of acteoside on locomotor recovery after spinal cord injury - The role of autophagy and apoptosis signaling pathway.

Biomed Pharmacother

Department of Spine Surgery, Tianjin Hospital, Tianjin University, Tianjin 300211, China. Electronic address:

Published: June 2024

AI Article Synopsis

  • The study explores the impact of acteoside, a phenylpropanoid glycoside, on locomotor recovery in rats with spinal cord injury (SCI) by examining factors like autophagy, apoptosis, inflammation, and oxidative stress.
  • After 28 days of treatment, results showed improved locomotor activity and notable changes in several protein levels related to these processes, suggesting that acteoside positively influences recovery.
  • Molecular docking studies indicated strong interactions between acteoside and key proteins involved in inflammation and apoptosis, highlighting its potential as a protective agent in SCI treatment, though further clinical validation is necessary.

Article Abstract

In the current study, we investigated the effects of acteoside as a phenylpropanoid glycoside on interaction with neurons to assesses locomotor recovery after spinal cord injury (SCI) in rats by focusing on evaluating the factors involved in autophagy, apoptosis, inflammation and oxidative stress processes. 49 Spargue-Dawley rats were prepared and divided into seven healthy and SCI groups receiving different concentrations of acteoside. After 28 days of disease induction and treatment with acteoside, a BBB score test was used to evaluate locomotor activity. Then, by preparing spinal cord cell homogenates, the expression levels of MAP1LC3A, MAP-2, glial fibrillary acidic protein (GFAP), Nrf2, Keap-1, Caspase 3 (Casp3), Bax, Bcl-2, TNF-a, IL-1B, reactive oxygen species (ROS), and malondialdehyde (MDA) were measured. Improvement of locomotor activity in SCI rats receiving acteoside was observed two weeks after the beginning of the experiment and continued until the fourth week. Both MAP1LC3A and MAP-2 were significantly up-regulated in SCI rats treated with acteoside compared to untreated SCI rats, and GFAP levels were significantly decreased in these animals. Pro-apoptotic proteins Bax and Casp3 and anti-apoptotic protein Bcl-2 were down-regulated and up-regulated, respectively, in SCI rats receiving acteoside. In addition, a significant downregulation of iNOS, TNF-α, and IL-1β and a decrease in contents of both ROS and MDA as well as increases in Nrf2 and Keap-1 were seen in rats receiving acteoside. Furthermore, acteoside strongly interacted with MAP1LC3A, TNF-α, and Casp3 targets with binding affinities of -8.3 kcal/mol, -8.3 kcal/mol, and -8.5 kcal/mol, respectively, determined by molecular docking studies. In general, it can be concluded that acteoside has protective effects in SCI and can be considered as an adjuvant therapy in the treatment of this disease. However, more studies, especially clinical studies, are needed in this field.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2024.116607DOI Listing

Publication Analysis

Top Keywords

sci rats
20
spinal cord
12
rats receiving
12
receiving acteoside
12
acteoside
9
effects acteoside
8
locomotor recovery
8
recovery spinal
8
cord injury
8
autophagy apoptosis
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!